Compare Novavax Inc (NVAX) vs Zillow Group Inc Class C (Z) Price & Performance

Novavax (NVAX) trades at $7.97, up 1.01% with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported strong Q2 2026 results, beating revenue and earnings estimates while raising full-year guidance. Despite negative profitability metrics, valuation ratios appear attractive with P/E of 3.14 and EV/EBITDA of 1.72. Recent news highlights progress with Sanofi partnership and cost reduction initiatives.

The outlook remains challenged by negative cash flows and accumulated deficits, but analyst sentiment is positive with 74% buy ratings. Key risks include ongoing operational losses and vaccine demand volatility, while potential upside exists from partnership milestones and adjuvant platform expansion. The stock presents a high-risk opportunity with significant analyst support despite fundamental weaknesses.

Zillow Group (Z) trades at $33.10, down 1.93% on the day, with a bearish technical signal and mixed earnings history. Revenue growth is solid, rising to $2.58B in 2025, but profitability remains thin with a net margin of 1.96%. The stock faces headwinds from a securities class action lawsuit and a challenging real estate market, though analyst consensus points to significant upside with a $52 price target.

The outlook is cautious due to legal risks and weak near-term profitability, but long-term monetization potential and analyst optimism suggest opportunity if execution improves. Key risks include litigation outcomes and market volatility, while institutional sentiment leans neutral with a 50% hold rating.